{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:12:44Z","timestamp":1769170364887,"version":"3.49.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"9","funder":[{"name":"Jeanne et J.-Louis L\u00e9vesque Perinatal Research Chair"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2022-1305_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Placental growth factor (PlGF) is used for first-trimester preeclampsia screening and could be combined with other biochemical markers for Down syndrome screening. We aim to estimate the predictive value of the combination of pregnancy-associated plasma protein (PAPP-A), free \u03b2-human chorionic gonadotropin (free \u03b2-hCG), placental growth factor (PlGF) and \u03b1-fetoprotein (AFP) with and without nuchal translucency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1305_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Singleton pregnancies recruited at 11\u201314\u00a0weeks and followed until delivery. The four maternal markers were measured using Kryptor (ThermoFisher-BRAHMS) and adjusted for gestational age and maternal characteristics. The risk of Down syndrome was calculated using the Fetal Medicine Foundation algorithm and multivariate linear regression analyses in all cases and in 2,200 controls. Receiver-operator characteristic (ROC) curves were used to calculate the detection and false-positive rates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1305_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-six (0.2%) cases of Down syndrome were diagnosed among 13,386 participants. The combination of the four biomarkers could have detected 88% (95% CI: 72\u201397%) of the cases at a false-positive rate of 13% (95% CI: 12\u201315%). The addition of nuchal translucency would have increased the detection rate to 96% (95% CI: 82\u201399%) at a false-positive rate of 4% (95% CI: 4\u20135%) using a 1:300 cut-off and to 100% (95% CI: 89\u2013100%) at a false-positive rate of 6% (95% CI: 5\u20138%) using a 1:500 cut-off.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1305_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>First-trimester screening using biochemical markers allows the identification of approximately 88% of Down syndrome cases for a false-positive rate of 13%. The addition of nuchal translucency raises the detection rate above 95% with a false-positive rate below 5%.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2022-1305","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T19:06:15Z","timestamp":1680116775000},"page":"1630-1635","source":"Crossref","is-referenced-by-count":4,"title":["First-trimester screening for Down syndrome using quadruple maternal biochemical markers"],"prefix":"10.1515","volume":"61","author":[{"given":"Laurence","family":"Caron","sequence":"first","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Fillion","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , Gynecology and Reproduction , Faculty of Medicine , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Gigu\u00e8re","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"},{"name":"Department of Molecular Biology , Medical Biochemistry and Pathology , Faculty of Medicine , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Audibert","sequence":"additional","affiliation":[{"name":"CHU Ste-Justine-Universit\u00e9 de Montr\u00e9al , Montr\u00e9al , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Forest","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"},{"name":"Department of Molecular Biology , Medical Biochemistry and Pathology , Faculty of Medicine , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Gasse","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Girard","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Laforest","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-4351","authenticated-orcid":false,"given":"Paul","family":"Guerby","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics , Paule de Viguier Hospital , CHU Toulouse , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-4369","authenticated-orcid":false,"given":"Emmanuel","family":"Bujold","sequence":"additional","affiliation":[{"name":"Reproduction , Mother and Child Health Unit , CHU De Qu\u00e9bec - Universit\u00e9 Laval Research Center , Universit\u00e9 Laval , Quebec , QC , Canada"},{"name":"Department of Obstetrics , Gynecology and Reproduction , Faculty of Medicine , Universit\u00e9 Laval , Quebec , QC , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2024030716131141971_j_cclm-2022-1305_ref_001","doi-asserted-by":"crossref","unstructured":"Nicolaides, KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005;29:190\u20134. https:\/\/doi.org\/10.1053\/j.semperi.2005.06.001.","DOI":"10.1053\/j.semperi.2005.06.001"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_002","doi-asserted-by":"crossref","unstructured":"Nicolaides, KH, Spencer, K, Avgidou, K, Faiola, S, Falcon, O. Multicenter study of first-trimester screening for trisomy 21 in 75, 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221\u20136. https:\/\/doi.org\/10.1002\/uog.1860.","DOI":"10.1002\/uog.1860"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_003","doi-asserted-by":"crossref","unstructured":"Rink, BD, Norton, ME. Screening for fetal aneuploidy. Semin Perinatol 2016;40:35\u201343. https:\/\/doi.org\/10.1053\/j.semperi.2015.11.006.","DOI":"10.1053\/j.semperi.2015.11.006"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_004","doi-asserted-by":"crossref","unstructured":"Boutin, A, Demers, S, Gasse, C, Gigu\u00e8re, Y, T\u00e9tu, A, Laforest, G, et al.. First trimester screening for fetal aneuploidies using placental growth factor: the Great Obstetrical Syndrome (GOS) Study. J Obstet Gynaecol Can 2018;40:1044\u20139. https:\/\/doi.org\/10.1016\/j.jogc.2017.11.032.","DOI":"10.1016\/j.jogc.2017.11.032"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_005","doi-asserted-by":"crossref","unstructured":"Badeghiesh, A, Volodarsky-Perel, A, Lasry, A, Hemmings, R, Gil, Y, Balayla, J. Use of placental growth factor for trisomy 21 screening in pregnancy: a systematic review. Am J Perinatol Rep 2020;10:e234\u201340. https:\/\/doi.org\/10.1055\/s-0040-1713785.","DOI":"10.1055\/s-0040-1713785"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_006","doi-asserted-by":"crossref","unstructured":"Bredaki, FE, Wright, D, Matos, P, Syngelaki, A, Nicolaides, KH. First-trimester screening for trisomy 21 using alpha-fetoprotein. Fetal Diagn Ther 2011;30:215\u20138. https:\/\/doi.org\/10.1159\/000330198.","DOI":"10.1159\/000330198"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_007","doi-asserted-by":"crossref","unstructured":"Yamamoto, R, Ohkouchi, T, Tabata, K, Ebina, Y, Watari, H, Kudo, M, et al.. A study of oligosaccharide variants of alpha-fetoproteins produced by normal fetuses and fetuses with trisomy 21. Acta Obstet Gynecol Scand 2005;84:1145\u20139. https:\/\/doi.org\/10.1111\/j.0001-6349.2005.00815.x.","DOI":"10.1111\/j.0001-6349.2005.00815.x"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_008","doi-asserted-by":"crossref","unstructured":"Suresh, S, Cuckle, HS, Jagadeesh, S, Ghosh, K, Vemavarapu, G, Taval, T, et al.. Down\u2019s syndrome screening in the first trimester with additional serum markers: Indian parameters. J Obstet Gynaecol India 2020;70:12\u20137. https:\/\/doi.org\/10.1007\/s13224-018-1198-1.","DOI":"10.1007\/s13224-018-1198-1"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_009","doi-asserted-by":"crossref","unstructured":"Donalson, K, Turner, S, Morrison, L, Liitti, P, Nilsson, C, Cuckle, H. Maternal serum placental growth factor and \u03b1-fetoprotein testing in first trimester screening for Down syndrome. Prenat Diagn 2013;33:457\u201361. https:\/\/doi.org\/10.1002\/pd.4087.","DOI":"10.1002\/pd.4087"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_010","doi-asserted-by":"crossref","unstructured":"Johnson, J, Pastuck, M, Metcalfe, A, Connors, G, Krause, R, Wilson, D, et al.. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. Prenat Diagn 2013;33:1044\u20139. https:\/\/doi.org\/10.1002\/pd.4194.","DOI":"10.1002\/pd.4194"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_011","doi-asserted-by":"crossref","unstructured":"Wright, D, Syngelaki, A, Bradbury, I, Akolekar, R, Nicolaides, KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 2014;35:118\u201326. https:\/\/doi.org\/10.1159\/000357430.","DOI":"10.1159\/000357430"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_012","doi-asserted-by":"crossref","unstructured":"Huang, T, Dennis, A, Meschino, WS, Rashid, S, Mak-Tam, E, Cuckle, H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-\u03b2 human chorionic gonadotrophin, placental growth factor, and \u03b1-fetoprotein. Prenat Diagn 2015;35:709\u201316. https:\/\/doi.org\/10.1002\/pd.4597.","DOI":"10.1002\/pd.4597"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_013","doi-asserted-by":"crossref","unstructured":"Palomaki, GE, Eklund, EE, Neveux, LM, Lambert Messerlian, GM. Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures. Prenat Diagn 2015;35:789\u201396. https:\/\/doi.org\/10.1002\/pd.4609.","DOI":"10.1002\/pd.4609"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_014","doi-asserted-by":"crossref","unstructured":"Carmichael, JB, Liu, HP, Janik, D, Hallahan, TW, Nicolaides, KH, Krantz, DA. Expanded conventional first trimester screening. Prenat Diagn 2017;37:802\u20137. https:\/\/doi.org\/10.1002\/pd.5090.","DOI":"10.1002\/pd.5090"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_015","doi-asserted-by":"crossref","unstructured":"Boutin, A, Demers, S, Gasse, C, Giguere, Y, Tetu, A, Laforest, G, et al.. First-trimester placental growth factor for the prediction of preeclampsia in nulliparous women: the Great Obstetrical Syndromes Cohort Study. Fetal Diagn Ther 2019;45:69\u201375. https:\/\/doi.org\/10.1159\/000487301.","DOI":"10.1159\/000487301"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_016","doi-asserted-by":"crossref","unstructured":"Boutin, A, Gasse, C, Demers, S, Blanchet, G, Gigu\u00e8re, Y, Bujold, E. Does low PAPP-A predict adverse placenta-mediated outcomes in a low-risk nulliparous population? The Great Obstetrical Syndromes (GOS) Study. J Obstet Gynaecol Can 2018;40:663\u20138. https:\/\/doi.org\/10.1016\/j.jogc.2017.08.047.","DOI":"10.1016\/j.jogc.2017.08.047"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_017","doi-asserted-by":"crossref","unstructured":"Boutin, A, Gasse, C, Guerby, P, Giguere, Y, Tetu, A, Bujold, E. First-trimester preterm preeclampsia screening in nulliparous women: the Great Obstetrical Syndrome (GOS) Study. J Obstet Gynaecol Can 2021;43:43\u20139. https:\/\/doi.org\/10.1016\/j.jogc.2020.06.011.","DOI":"10.1016\/j.jogc.2020.06.011"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_018","doi-asserted-by":"crossref","unstructured":"Boutin, A, Guerby, P, Gasse, C, Tapp, S, Bujold, E. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes Cohort Study. Am J Obstet Gynecol 2021;224:204 e1\u20137. https:\/\/doi.org\/10.1016\/j.ajog.2020.08.008.","DOI":"10.1016\/j.ajog.2020.08.008"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_019","doi-asserted-by":"crossref","unstructured":"Wang, L, Xu, J, Niu, W, Hu, L, Zhang, Y, Sun, Y. Genetic testing on products of conception and its relationship with body mass index. J Assist Reprod Genet 2020;37:1853\u201360. https:\/\/doi.org\/10.1007\/s10815-020-01849-9.","DOI":"10.1007\/s10815-020-01849-9"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_020","doi-asserted-by":"crossref","unstructured":"Mazer Zumaeta, A, Wright, A, Syngelaki, A, Maritsa, VA, Bardani, E, Nicolaides, KH. Screening for trisomy at 11\u201313\u00a0weeks\u2019 gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol 2020;56:408\u201315. https:\/\/doi.org\/10.1002\/uog.22140.","DOI":"10.1002\/uog.22140"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_021","doi-asserted-by":"crossref","unstructured":"Huang, T, Dennis, A, Meschino, WS, Rashid, S, Mak-Tam, E, Cuckle, H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-beta human chorionic gonadotrophin, placental growth factor, and alpha-fetoprotein. Prenat Diagn 2015;35:709\u201316. https:\/\/doi.org\/10.1002\/pd.4597.","DOI":"10.1002\/pd.4597"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_022","doi-asserted-by":"crossref","unstructured":"Gareau-Leonard, A, Fillion, A, Labine, L, Gasse, C, Demers, S, Bujold, E. Evolution of Down syndrome prenatal screening clinical practices in Quebec. J Obstet Gynaecol Can 2020;42:439\u201345. https:\/\/doi.org\/10.1016\/j.jogc.2019.09.025.","DOI":"10.1016\/j.jogc.2019.09.025"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_023","doi-asserted-by":"crossref","unstructured":"Davies, V, Gledhill, J, McFadyen, A, Whitlow, B, Economides, D. Psychological outcome in women undergoing termination of pregnancy for ultrasound-detected fetal anomaly in the first and second trimesters: a pilot study. Ultrasound Obstet Gynecol 2005;25:389\u201392. https:\/\/doi.org\/10.1002\/uog.1854.","DOI":"10.1002\/uog.1854"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_024","doi-asserted-by":"crossref","unstructured":"Bujold, E, Roberge, S, Lacasse, Y, Bureau, M, Audibert, F, Marcoux, S, et al.. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402\u201314. https:\/\/doi.org\/10.1097\/aog.0b013e3181e9322a.","DOI":"10.1097\/AOG.0b013e3181e9322a"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_025","doi-asserted-by":"crossref","unstructured":"Roberge, S, Bujold, E, Nicolaides, KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018;218:287\u201393 e1. https:\/\/doi.org\/10.1016\/j.ajog.2017.11.561.","DOI":"10.1016\/j.ajog.2017.11.561"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_026","doi-asserted-by":"crossref","unstructured":"Roberge, S, Nicolaides, K, Demers, S, Hyett, J, Chaillet, N, Bujold, E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017;216:110\u201320 e6. https:\/\/doi.org\/10.1016\/j.ajog.2016.09.076.","DOI":"10.1016\/j.ajog.2016.09.076"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_027","doi-asserted-by":"crossref","unstructured":"Roberge, S, Nicolaides, KH, Demers, S, Villa, P, Bujold, E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41:491\u20139. https:\/\/doi.org\/10.1002\/uog.12421.","DOI":"10.1002\/uog.12421"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_028","doi-asserted-by":"crossref","unstructured":"Rolnik, DL, Wright, D, Poon, LC, O\u2019Gorman, N, Syngelaki, A, de Paco Matallana, C, et al.. Aspirin versus placebo in pregnancies at\u00a0high risk for preterm preeclampsia. N Engl J Med 2017;377:613\u201322. https:\/\/doi.org\/10.1056\/nejmoa1704559.","DOI":"10.1056\/NEJMoa1704559"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_029","doi-asserted-by":"crossref","unstructured":"Rolnik, DL, Nicolaides, KH, Poon, LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol 2022;226:S1108\u201319. https:\/\/doi.org\/10.1016\/j.ajog.2020.08.045.","DOI":"10.1016\/j.ajog.2020.08.045"},{"key":"2024030716131141971_j_cclm-2022-1305_ref_030","doi-asserted-by":"crossref","unstructured":"Spencer, K, Heath, V, Flack, N, Ong, C, Nicolaides, KH. First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21. Prenat Diagn 2000;20:635\u20139. https:\/\/doi.org\/10.1002\/1097-0223(200008)20:8<635::aid-pd868>3.0.co;2-u.","DOI":"10.1002\/1097-0223(200008)20:8<635::AID-PD868>3.0.CO;2-U"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1305\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T16:15:42Z","timestamp":1709828142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1305\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,8,28]]}},"alternative-id":["10.1515\/cclm-2022-1305"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-1305","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}